Capital Performance Advisors LLP Invests $66,000 in Laboratory Co. of America Holdings (NYSE:LH)

Capital Performance Advisors LLP acquired a new stake in Laboratory Co. of America Holdings (NYSE:LH) during the 3rd quarter, Holdings Channel reports. The fund acquired 297 shares of the medical research company’s stock, valued at approximately $66,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Horizon Bancorp Inc. IN acquired a new position in shares of Laboratory Co. of America during the third quarter worth $29,000. Pathway Financial Advisers LLC acquired a new position in Laboratory Co. of America in the 1st quarter worth about $30,000. Industrial Alliance Investment Management Inc. bought a new position in Laboratory Co. of America in the second quarter valued at about $27,000. Innealta Capital LLC acquired a new stake in shares of Laboratory Co. of America during the second quarter valued at about $32,000. Finally, Riverview Trust Co grew its holdings in shares of Laboratory Co. of America by 172.6% during the third quarter. Riverview Trust Co now owns 169 shares of the medical research company’s stock worth $38,000 after purchasing an additional 107 shares during the last quarter. Institutional investors own 95.94% of the company’s stock.

Insider Buying and Selling

In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 2,000 shares of Laboratory Co. of America stock in a transaction on Monday, August 19th. The shares were sold at an average price of $227.05, for a total transaction of $454,100.00. Following the transaction, the executive vice president now directly owns 3,670 shares of the company’s stock, valued at $833,273.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 2,000 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $227.05, for a total value of $454,100.00. Following the completion of the sale, the executive vice president now owns 3,670 shares in the company, valued at approximately $833,273.50. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Glenn A. Eisenberg sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $223.99, for a total value of $3,359,850.00. Following the completion of the transaction, the chief financial officer now owns 31,289 shares in the company, valued at $7,008,423.11. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,000 shares of company stock worth $4,043,950. 0.85% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on LH shares. Bank of America raised their price objective on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the company a “buy” rating in a report on Monday, August 5th. Truist Financial lifted their price target on shares of Laboratory Co. of America from $255.00 to $275.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. StockNews.com cut shares of Laboratory Co. of America from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. HSBC upgraded shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a report on Wednesday, October 30th. Finally, Evercore ISI decreased their price target on Laboratory Co. of America from $250.00 to $240.00 and set an “in-line” rating for the company in a report on Tuesday, September 24th. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $255.92.

Laboratory Co. of America Stock Performance

LH opened at $242.39 on Friday. Laboratory Co. of America Holdings has a 1-year low of $191.97 and a 1-year high of $243.78. The company has a market cap of $20.27 billion, a price-to-earnings ratio of 46.88, a PEG ratio of 1.93 and a beta of 1.05. The company’s fifty day moving average price is $223.02 and its two-hundred day moving average price is $214.30. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.66.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.02. The business had revenue of $3.28 billion for the quarter, compared to analysts’ expectations of $3.26 billion. Laboratory Co. of America had a net margin of 3.43% and a return on equity of 15.27%. The firm’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter last year, the firm earned $3.38 EPS. On average, analysts expect that Laboratory Co. of America Holdings will post 14.53 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Tuesday, November 26th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $2.88 annualized dividend and a yield of 1.19%. Laboratory Co. of America’s dividend payout ratio (DPR) is currently 55.71%.

Laboratory Co. of America Company Profile

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.